Data on plasma tumour and metabolism related proteins’ potential in differentiation of HFpEF-PH from PAH and in prognosis of left heart failure patients with pulmonary hypertension

The data in the current paper constitutes supplementary material to our article entitled “Plasma tumour and metabolism related biomarkers AMBP, LPL and Glyoxalase I differentiate heart failure with preserved ejection fraction with pulmonary hypertension from pulmonary arterial hypertension” Ahmed et al. (2021). The study investigated 69 plasma tumour- and metabolism related proteins in healthy controls (n = 20) and in 115 patients of whom 48 had pulmonary arterial hypertension (PAH; n = 48) and 67 with left heart failure with pulmonary hypertension (LHF-PH) [heart failure with- preserved ejection fraction-PH (HFpEF-PH; n = 31) and reduced ejection fraction-PH (HFrEF-PH; n = 36)]. The haemodynamic data were obtained with right heart catheterization, and clinical data from medical records. The present article describe the plasma levels of tumour- and metabolism related proteins, analyzed with proximity extension assay, along with their uni- and multivariable diagnostic and prognostic potential. High sRAGE levels univariably emerged as a negative prognostic marker in LHF-PH.